TDP-35, a truncated fragment of TDP-43, induces dose-dependent toxicity and apoptosis in flies

Deepak Chhangani, Diego E. Rincon-Limas

TAR DNA-binding protein 43 (TDP-43) is an essential 414 amino acid protein that regulates multiple aspects of RNA biogenesis, processing, and transport. It localizes primarily in the nucleus, but abnormal translocation and accumulation in the cytosol occur under pathological conditions (Tiorzouda et al., 2021). TDP-43 abnormalities are typical pathological hallmarks of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. Mutations in the TDP-43 encoding gene TARDBP cause familial ALS, while wild-type TDP-43 is associated with almost all (~97%) of sporadic ALS cases and nearly half of frontotemporal lobar degeneration patients (~45%) (de Boer et al., 2020). Extensive research has identified post-translational modifications of TDP-43 such as phosphorylation, ubiquitination and truncation as major histopathological characteristics in TDP-43 proteinopathies. Substantial progress has occurred in studying protein aggregation involving phosphorylated and ubiquitinated TDP-43. However, as recently discussed by us, the relevance and pathological role of truncated TDP-43 forms are still poorly understood (Chhangani et al., 2021). Here we extend our discussion on truncation of TDP-43, present new experimental insights into the neurotoxic role of its cleaved TDP-35 fragment, and provide a perspective on new avenues of research in this field.

TDP-43 proteinopathies display prominent depletion of nuclear TDP-43, post-translational modifications, and cytosolic aggregation involving protein-protein and protein-RNA interactions. Truncation of TDP-43 may influence these processes, and different truncated forms may exert different degrees of toxicity (Igaz et al., 2009), suggesting a need to conduct thorough studies targeting individual TDP-43 fragments. Truncated TDP-43 species may range from 15–43 kDa in size. The 25 kDa and 35 kDa fragments, also known as TDP-25 and TDP-35, respectively, appear to be the most prominent ones. Three types of peptidases that include asparaginyl endopeptidase, Calpains (I, II) and Caspases (3, 4, 7) are known to cleave TDP-43 at a minimum of 28 different sites along the length of the protein. Cleavage by these peptidases can generate an array of C-terminal fragments (CTFs) and N-terminal fragments (NTFs). Igaz et al. (2009) reported the discovery of a wide range of CTFs in postmortem brain samples from patients with neurodegenerative conditions. Since then, multiple studies have confirmed the presence of TDP-43 truncated forms in patients with a variety of neurodegenerative maladies. A more recent mass spectrometry analysis suggested that the N-terminal end of TDP-43 is more accessible to proteases (Kametani et al., 2016). This property increases the likelihood of proteolytic cleavage at the N-terminus, making CTFs the primary products. As for NTFs, their full-length TDP-43 has its functional consequence. Consequently, truncated forms that lack the N-terminal end can interact to form amyloid-like structures and associated aggregates. Processes such as these that lead to the aggregation of truncated forms essentially result in a toxic gain-of-function. Since these aggregates also sequester full-length TDP-43, they may further obstruct the protein’s normal regulatory functions. Regardless of the exact mechanisms involved, both N- and C-terminal fragments may lead to cellular toxicity by either a gain-of-function or a loss-of-function. Therefore, a comprehensive characterization of truncated TDP-43 forms is of paramount importance.

TDP-43 fragments are also present in several other neurodegenerative conditions: Alzheimer’s disease, corticobasal degeneration, Parkinson’s disease, Pick’s disease, and traumatic brain injury (Chhangani et al., 2021). While TDP-43 truncated forms are not the primary causative agents in these diseases, TDP-43 truncated forms may play an essential secondary role by exacerbating disease progression. Indeed, recent studies suggest that truncated TDP-43 species can serve as biomarkers for certain TDP-43 proteinopathies, even if the precise pathogenic role of these fragments is unclear (Feneberg et al., 2021). Furthermore, several in vitro and in vivo studies suggest that TDP-43 fragments are neurotoxic (Igaz et al., 2009; Medina et al., 2014; Zhang et al., 2009). However, insights on their pathomechanisms remain elusive and controversial since cleavage of TDP-43 could be an irrelevant byproduct of other cellular processes. For instance, cells may initiate apoptotic pathways in response to various stressors, activating caspases that cleave TDP-43.

We recently published a review on TDP-43 fragmentation that highlights its relevance and potential implications in neurodegeneration (Chhangani et al., 2021). We deduced that the heterogeneity of TDP-43 fragments leaves us with two fundamental questions. First, how are these different truncated forms produced? Second, what roles do these TDP-43 fragments play in neurodegeneration? Apart from the proteolytic cleavage of full-length TDP-43, we know very little about the origin of these truncated forms. A combination of protease-dependent and -independent mechanisms are potentially involved since there are several TDP-43 cleavage products associated with ALS and frontotemporal lobar degeneration without candidate proteases. Either investigators have not found the relevant proteases or non-enzymatic mechanisms are also involved. Recent studies have found that alternative splicing can also produce TDP-35 (Xiao et al., 2015; Weskamp et al., 2020). Interestingly, these studies describe at least two different splice variants of the TDP-43 transcript that produce different neurotoxic TDP-35 species. These findings introduce another layer of complexity by showing that both post-transcriptional and post-translational modifications are involved.

Several in vitro and in vivo studies have shown that cleaved TDP-25 fragments are toxic and can induce disease-like symptoms in animals, but only a few have addressed the role of TDP-35 (Chhangani et al., 2021). In one such study, Crippa et al. (2016) created transgenic flies that expresses full-length TDP-43 and its truncated TDP-35 product from the same genomic locus, allowing similar expression levels to facilitate proper comparison of phenotypes. They found that TDP-35 is significantly more toxic than TDP-43 when expressed in the *Drosophila* eye, resulting in pupal lethality (Crippa et al., 2016). Motivated by this finding, we obtained these flies (a gift from Serena Carra) to compare the effects of different expression levels. These fly models employ the binary UAS-Gal4 system to control the expression of TDP-43 and TDP-35 transgenes. Furthermore, the UAS-Gal4 system induces expression in a temperature-dependent manner, with higher Gal4 activity in flies cultured at higher temperatures. Therefore, we used the eye-specific gmr-Gal4 driver to activate expression of TDP-43 and the innocuous LacZ control transgene in photoreceptor neurons at 22°C, 25°C and 27°C. As shown in Figure 1, we found that LacZ and wild-type TDP-43 did not affect eye morphology at any temperature, except for minor degeneration at the highest temperature (27°C) for TDP-43-expressing flies (Figure 1A, arrows). In contrast, TDP-35 was increasingly toxic with a direct relationship to temperature and its associated expression level. Specifically, TDP-35 triggered disorganization of the retinal omatidial array at 22°C, extensive necrotic patches at 25°C, and pupal lethality with complete neurodegeneration at 27°C (Figure 1A, arrows in bottom row). To test whether TDP-35 induces apoptosis in *Drosophila* photoreceptor neurons, we...
used the GC3Ai apotosensor to quantify the extent of apoptosis in larval eye imaginal discs expressing each transgene. The GC3Ai apotosensor is a sensitive GFP-based marker that responds specifically to apoptosis (Schott et al., 2017) and thus we used it in larval stages prior to pupal lethality. As expected, we detected higher levels of apoptosis in the eye primordium of TDP-35-expressing eyegonial discs compared to TDP-43 or LacZ specimens (Figure 1A and B). These results are not due to differences in expression levels as the transgenes are inserted as single copies in the same genomic landing site. Moreover, all the flies were grown and treated in parallel under shared culture conditions to rule out batch effects and other artifacts. Therefore, these results demonstrate the robust ability of TDP-35 to hamper cellular homeostasis, resulting in cell death.

These results and the flexibility of our experimental system open the possibility of conducting a systematic comparative analysis of all truncated TDP-43 variants. To do this, we would generate additional transgenic lines encoding other TDP-43 fragments, either by enzymatic cleavage or by alternative transcriptional splicing. Importantly, all transgenic flies would be created by inserting transgenes at the same chromosomal landing site used for the existing TDP-35-expressing flies (S1D) to ensure similar transgene expression levels for a given set of conditions. Furthermore, it could also be possible to create flies with transgenes that express multiple TDP-43 fragments to evaluate potential synergistic or additive effects, although this will require the use of conditional expression systems to bypass developmental toxicity. A variety of mechanistic studies are also anticipated to understand the molecular basis of TDP-35-induced cell death.

In conclusion, this study provides additional experimental evidence demonstrating the neurotoxic potential of TDP-35 in vivo. This toxicity seems to be dose-dependent; therefore, the presence of TDP-35 fragments beyond certain thresholds in humans could affect neuronal health and may aggravate the course of TDP-35 proteinopathies. Of note, the TDP-35 transgene discussed here could also be used to investigate its role in the context of other fly models of human neurodegenerative disorders characterized by proteinopathies that involve TDP-43 fragments, such as Alzheimer’s disease. While Drosophila provides excellent experimental platforms to study neurodegenerative conditions, we encourage others to use different model organisms to verify our findings in flies and to fully understand the enigmatic role of truncated TDP-43 fragments in neurodegeneration.

This work was supported by National Institutes of Health grant R01AG059871 (to DRL).

Deepak Chhangani, Diego E. Rincon-Limas*
Department of Neurology, McKnight Brain Institute, and Norman Faxel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA (Chhangani D)
Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, Genetics Institute, University of Florida, Gainesville, FL, USA (Rincon-Limas DE)
*Correspondence to: Diego E. Rincon-Limas, PhD, diego.rincon@neurology.ufl.edu.
https://orcid.org/0000-0003-3971-7589
(Deeak Chhangani)
https://orcid.org/0000-0003-3099-0642
(Diego E. Rincon-Limas)
Date of submission: October 8, 2021
Date of decision: November 5, 2021

References
Chhangani D, Martin-Peña A, Rincon-Limas DE (2021) Molecular, functional and pathological aspects of TDP-43 fragmentation. iScience 24:102459.
Crippa V, Cicardi ME, Ramesh N, Seguin S, Migi B, Diacci C, Zelotti E, Baratastvelli M, Gregory JM, Dobson CM, Cereda C, Pandey UB, Poletti A, Carra S (2016) The chaperone HSPB1 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Hum Mol Genet 25:3908-3924.
de Boer EM, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvkloski T, Silvsky M, Menon P, van den Bos M, Halliday GM, van den Berg LH, Van Den Bosch L, van Damme F, Kiernan MC, van Es MA, Vucic S (2020) TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 92:86-95.
Feneberg E, Charles PD, Finelli MJ, Scott C, Kessler BM, Frischer P, Anorsge O, Gr多重 E, Talbot K, Turner MR (2021) Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP Brain Pathol 31:e12923.
Igaz LM, Kwong UK, Chen-Piotiekin A, Winton M, Jnger TL, Xu Y, Neumann M, Trojanowski JQ, Lee YM (2009) Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem 284:8516-8524.
Kametani F, Ohi T, Shishidzhi T, Akatsu H, Murayama S, Saito Y, Yoshida M, Hasegawa M (2016) Mass spectrometric analysis of accumulated TDP-43 in Amyotrophic lateral sclerosis brains. Sci Rep 6:22381.
Medina DX, Orr ME, Oddo S (2014) Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol Aging 35:79-87.
Schott S, Ambrosini A, Barbaste A, Benyasavag C, Gracia M, Proag A, Rayer M, Monier B, Suzanne M (2017) A fluorescent reporter for spatiotemporal tracking of apoptotic cells in living Drosophila tissues. Development 144:3840-3846.
Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 22:197-208.
Weskamp K, Tan EM, Miguez R, McBride JP, Gomez NB, White M, Lin Z, Gonzalez CM, Serio A, Sreedharam J, Barnada SJ (2020) Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J Clin Invest 130:1139-1155.
Xiao S, Sannell T, Chiang H, Sun Y, Chakraborty A, Keith JM, Rogeav E, Zinman L, Robertson J (2015) Low molecular weight species of TDP-43 generated by ablative splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol 130:49-61.
Zhang Y-J, Xu Y-F, Cook G, Gendron TF, Roettges P, Link CL, W-Y-W-L, Tong I, Castanoves-Casney P, Gass J, Rangachari V, Buratto E, Baralle F, Golde TE, Dickson DW, Petruccelli L (2009) Ablern cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 106:7607-7612.

P-Reviewer: Shukla A; C-Editors: Zha M, Liu W, Li Y; F-Editor: Jia Y